### Edgar Filing: CHAMPSI FARAH - Form 4

CHAMPSI F Form 4	ARAH									
April 16, 201										PROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMIS Washington, D.C. 20549							OMMISSION	OMB Number:	3235-0287	
Washington, D.C. 20549 Number:								•		
(Print or Type F	Responses)									
CHAMPSI FARAH Symbol			er Name <b>and</b> Ticker or Trading ERIX INC [CMRX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (M	/liddle)	3. Date of Earliest Transaction					sk an applicable)		
	ARCADERO 37TH FLOOR		(Month/D 04/16/20	•				X Director Officer (give below)		Owner er (specify
SAN FRAN	(Street)	11		ndment, Da th/Day/Year	-			6. Individual or Jo Applicable Line) _X_ Form filed by O Form filed by M Person	One Reporting Pe	rson
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative Se	curiti	es Acqu	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution I any (Month/Day/Sear)		n Date, if Transaction(A) or Disposed of Code (Instr. 3, 4 and 5)			of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	04/16/2013			Code V C	Amount 826,474	(D) A	Price ( <u>1</u> )	826,474	Ι	See Footnote
Common Stock	04/16/2013			С	688,729	А	<u>(3)</u>	1,515,203	I	See Footnote
Common Stock	04/16/2013			С	550,982	А	<u>(4)</u>	2,161,829 (5)	I	See Footnote

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: CHAMPSI FARAH - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	ransactionDerivative ode Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D Preferred Stock	<u>(1)</u>	04/16/2012		С		2,933,986	<u>(1)</u>	<u>(1)</u>	Common Stock	826,474
Series E Preferred Stock	<u>(3)</u>	04/16/2012		С		2,444,990	(3)	(3)	Common Stock	688,729
Series F Preferred Stock	<u>(4)</u>	04/16/2012		С		1,955,991	<u>(4)</u>	<u>(4)</u>	Common Stock	550,982

### **Reporting Owners**

Reporting Owner Name / Addres	s	Relationships						
	Director	10% Owner	Officer	Other				
CHAMPSI FARAH ONE EMBARCADERO CENT 37TH FLOOR SAN FRANCISCO, CA 94111	ER, X							
Signatures								
/s/ Farah 04/	/16/2013							

 <u>\*\*Signature of</u>
 Date

 Reporting Person
 Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Upon the closing of the Issuer's initial public offering, every 3.55 shares of Series D Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.

(2) See attached Exhibit 99.1

#### Edgar Filing: CHAMPSI FARAH - Form 4

- (3) Upon the closing of the Issuer's initial public offering, every 3.55 shares of Series E Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- (4) Upon the closing of the Issuer's initial public offering, every 3.55 shares of Series F Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.

Includes an aggregate of 95,644 shares issued as payment of accrued dividends on the Series F Preferred Stock held as follows: 87,602
(5) shares held by Alta Biopharma Partners III, L.P., 5,883 shares held by Alta Biopharma Partners III GmbH & Co. Beteiligungs KG and 2,159 shares held by Alta Embarcadero Biopharma Partners III, LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.